ONCAlert | Upfront Therapy for mRCC

Concurrent Durvalumab/RT Plus Adjuvant Durvalumab in Locally Advanced Urothelial Cancer of Bladder

Monika Joshi, MD, MRCP
Published Online: 3:29 AM, Fri February 14, 2020


Monika Joshi, MD, MRCP, associate professor of medicine, Division of Hematology-Oncology, and co-leader for Genitourinary Disease Team, at Penn State Hershey Cancer Institute, discusses the phase Ib/II results of a trial looking at concurrent durvalumab and radiation therapy followed by adjuvant durvalumab in patients with locally advanced urothelial cancer of the bladder.

In this study, durvalumab was administered along with radiation therapy for a 7-weeks-on/4-weeks-off schedule, Joshi says. After assessing for response, investigators moved to the adjuvant phase and administered durvalumab monthly to these patients for 1 year. Twenty-four patients were evaluable for response, 17 of which achieved complete responses; 25% of patients achieved partial response or stable disease. This led to a 95% disease control rate. However, these findings should be interpreted cautiously as longer follow-up is needed, she added.

Regarding safety, fatigue and lymphopenia were reported adverse events (AEs), and immune-related AEs were less common than expected on this trial, Joshi explains. Overall, the treatment was well tolerated. 

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.